Flagship Pioneering, a scientific innovation firm developing transformative platforms and products, and its subsidiary Etiome, which focuses on redefining how disease progression is detected and prevented, announced that Adrian “Ad” Rawcliffe has joined Flagship Pioneering as CEO-Partner and will also serve as Chief Executive Officer of Etiome. Noubar Afeyan, Ph.D., Co-founder of Etiome and Founder and CEO of Flagship Pioneering, said that Rawcliffe brings exceptional experience in translating groundbreaking science into real-world impact. He added that Rawcliffe’s expertise in guiding companies through transformative phases and his commitment to pioneering therapeutic innovations will help accelerate Etiome’s mission to advance preemptive healthcare.
Health Technology Insights: Celltrion Wins CHMP Support for SteQeyma Autoinjector
Rawcliffe has over twenty years of experience leading biotechnology organizations through scientific, strategic, and financial milestones. He most recently served as CEO of Adaptimmune Therapeutics, where he led the approval of the first engineered TCR T-cell therapy for solid tumors, executed multiple strategic partnerships and mergers, and raised around $1.3 billion through capital markets and business development. Previously, as CFO of Adaptimmune, he oversaw the company’s IPO and helped expand its workforce to more than 500 employees. Before joining Adaptimmune, Rawcliffe spent over fifteen years at GSK in senior global roles, including Senior Vice President of Finance for North American Pharmaceuticals, Senior Vice President of Worldwide Business Development and R&D Finance, and Managing Partner and President of SR One. At GSK, he pioneered option-based R&D partnerships and led numerous external innovation and venture initiatives.
Health Technology Insights: EDX Medical to Launch Advanced Bowel Cancer Test in UK
Avak Kahvejian, Ph.D., Founding CEO and Director of Etiome, President of Flagship Labs, and General Partner at Flagship Pioneering, said Rawcliffe is joining Etiome at a pivotal moment as the company scales its Temporal Biodynamics platform across key disease areas with unmet medical needs. Kahvejian noted that his leadership will help Etiome turn discoveries into therapies capable of changing disease progression and improving patient outcomes.
Rawcliffe stated that understanding and intervening in disease at the right moment opens a promising frontier in medicine. He expressed enthusiasm about working with Etiome’s team to translate these insights into a new generation of disease-modifying treatments that could redefine therapeutic intervention and enhance the patient experience.
Health Technology Insights: Cosan Secures Growth Funding to Expand AI Virtual Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
